Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines

Jin,Xin; Fang,Yong; Hu,Yi; Chen,Jing; Liu,Wei; Chen,Gang; Gong,Mei; Wu,Peng; Zhu,Tao; Wang,Shixuan; Zhou,Jianfeng; Wang,Hui; Ma,Ding; Li,Kezhen

doi:10.3892/ol.2017.6032

Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines

Authors:
- Xin Jin
- Yong Fang
- Yi Hu
- Jing Chen
- Wei Liu
- Gang Chen
- Mei Gong
- Peng Wu
- Tao Zhu
- Shixuan Wang
- Jianfeng Zhou
- Hui Wang
- Ding Ma
- Kezhen Li
View Affiliations

Affiliations: Cancer Biology Research Center, Key Laboratory of The Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: April 13, 2017 https://doi.org/10.3892/ol.2017.6032
Pages: 4619-4626
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although a combination of platinum- and taxane-based chemotherapy is recommended for at least 70% patients with ovarian cancer as treatment subsequent to surgery, the initial response to the chemotherapy is not durable and tumors become resistant. Histone deacetylase and proteasome inhibitors are novel therapeutic agents. However, the moderate antitumoral effect of the inhibitors has restricted their clinical use when used as single agents. The aim of the present study was to investigate the synergistic activity of trichostatin A (TSA) and PS‑341 in ovarian cancer cells, along with the investigation of the molecular mechanisms of taxane resistance. The taxane‑sensitive ovarian cancer A2780 cell line and its resistant variant, A2780T, were treated with taxane, TSA and PS‑341 at various concentrations. An Annexin V assay was performed to determine the levels of cell viability and apoptosis, while flow cytometry and immunofluorescence staining for the mitotic phase‑specific protein phosphorylated‑histone H3 (Ser10) were used for cell cycle detection. The effects of combined TSA and PS‑341 on cell cycle‑associated proteins were tested by western blot analysis. Furthermore, the present study examined the apoptosis and cell cycle arrest induced by the 3 agents subsequent to overexpression or downregulation of cyclin B1 in A2780 and A2780T cells, respectively. It was found that TSA interacted synergistically with PS‑341, resulting in a marked increase in apoptosis and the rate of G2/M arrest in A2780T cells. A lower basal level of cyclin B1 expression and the incompetence of the upregulation of the cyclin may explain the taxane resistance found in A2780T cells. Collectively, the combination of TSA and PS‑341 increased cyclin B1 expression level regardless of the basal expression level, resulting in the proliferation inhibition and apoptosis in A2780 and A2780T cells, which raised the possibility that a combination of the two drugs may represent a novel strategy for the treatment of ovarian cancer, particularly in taxane-resistant ovarian cancer.

View Figures

View References

1	Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP and Matei DE: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
3	Pchejetski D, Alfraidi A, Sacco K, Alshaker H, Muhammad A and Monzon L: Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J Cancer Res Clin Oncol. 142:1659–1671. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ma X, Ezzeldin HH and Diasio RB: Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs. 69:1911–1934. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wagner JM, Hackanson B, Lubbert M and Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 1:117–136. 2010. View Article : Google Scholar : PubMed/NCBI
6	Miller CP, Singh MM, Rivera-Del Valle N, Manton CA and Chandra J: Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol. 2011:5142612011. View Article : Google Scholar : PubMed/NCBI
7	Zhu K, Qu D, Sakamoto T, Fukasawa I, Hayashi M and Inaba N: Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors. Arch Gynecol Obstet. 277:15–19. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shahshahan MA, Beckley MN and Jazirehi AR: Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: Basic and clinical aspects. Am J Cancer Res. 1:913–924. 2011.PubMed/NCBI
9	Moody CA and Laimins LA: Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer. 10:550–560. 2010. View Article : Google Scholar : PubMed/NCBI
10	Russo A, Fratto ME, Bazan V, Schiro V, Agnese V, Cicero G, Vincenzi B, Tonini G and Santini D: Targeting apoptosis in solid tumors: The role of bortezomib from preclinical to clinical evidence. Expert Opin Ther Targets. 11:1571–1586. 2007. View Article : Google Scholar : PubMed/NCBI
11	Kao C, Chao A, Tsai CL, Lin CY, Chuang WC, Chen HW, Yen TC, Wang TH, Lai CH and Wang HS: Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. Cell Death Dis. 4:e5122013. View Article : Google Scholar : PubMed/NCBI
12	Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al: Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012. View Article : Google Scholar : PubMed/NCBI
13	Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, et al: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A north central cancer treatment group study. Neuro Oncol. 14:215–221. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sato A and Asano T, Ito K, Sumitomo M and Asano T: Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int. 109:1258–1268. 2012. View Article : Google Scholar : PubMed/NCBI
15	Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ and Eckhardt SG: Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 31:1093–1103. 2011.PubMed/NCBI
16	Kim J, Guan J, Chang I, Chen X, Han D and Wang CY: PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther. 9:1977–1984. 2010. View Article : Google Scholar : PubMed/NCBI
17	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nature Protoc. 1:2315–2319. 2006. View Article : Google Scholar
18	Schägger H: Tricine-SDS-PAGE. Nat Protoc. 1:16–22. 2006. View Article : Google Scholar : PubMed/NCBI
19	Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS and Ramos JC: Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. J Clin Invest. 123:2616–2628. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hui KF, Lam BH, Ho DN, Tsao SW and Chiang AK: Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther. 12:747–758. 2013. View Article : Google Scholar : PubMed/NCBI
21	Karthik S, Sankar R, Varunkumar K and Ravikumar V: Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 68:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
22	Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH and Landen CN: Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget. 5:7065–7080. 2014. View Article : Google Scholar : PubMed/NCBI
23	Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T and Venkitaraman AR: Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene. 31:2450–2460. 2012. View Article : Google Scholar : PubMed/NCBI
24	Androic I, Kramer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K and Yuan J: Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer. 8:3912008. View Article : Google Scholar : PubMed/NCBI
25	Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 60:4000–4004. 2000.PubMed/NCBI
26	Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S and Sasano H: Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 98:644–651. 2007. View Article : Google Scholar : PubMed/NCBI
27	Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang D and Ling C: Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer. 11:392012. View Article : Google Scholar : PubMed/NCBI
28	He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, et al: Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 7:e310872012. View Article : Google Scholar : PubMed/NCBI
29	Cloos CR, Daniels DH, Kalen A, Matthews K, Du J, Goswami PC and Cullen JJ: Mitochondrial DNA depletion induces radioresistance by suppressing G2 checkpoint activation in human pancreatic cancer cells. Radiat Res. 171:581–587. 2009. View Article : Google Scholar : PubMed/NCBI
30	Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
31	Huang HC, Shi J, Orth JD and Mitchison TJ: Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell. 16:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
32	Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010. View Article : Google Scholar : PubMed/NCBI